Talha Memon, MD
Sleep Medicine · Murrieta, CANPI 1922410869
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,879 of the $4,535 with a category attached, or 63.5%. 16 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 53.3% of the total. Reporting peaked in 2020 at $1,349 and has fallen 54.4% since, to $616 in 2025.
Across 124 payments — averaging $36.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- Jazz Pharmaceuticals Inc.$1K
- Harmony Biosciences LLC$339
- Arbor Pharmaceuticals, Inc.$105
- Eisai Inc.$75
- Idorsia Pharmaceuticals US Inc$71
- plus $366 from 10 others
What the payments were for
- Travel & lodging$96221%
- Food & beverage$2,87963%
- Education$69515%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 43 | $2,417 |
| Jazz Pharmaceuticals Inc. | 41 | $1,161 |
| Harmony Biosciences LLC | 11 | $339 |
| Arbor Pharmaceuticals, Inc. | 5 | $105 |
| Eisai Inc. | 4 | $75 |
| Idorsia Pharmaceuticals US Inc | 4 | $71 |
| Resmed Corp | 2 | $69 |
| GSK | 1 | $63 |
| Noctrix Health, Inc. | 3 | $61 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Fisher & Paykel Healthcare Inc | 3 | $43 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Itamar Medical Inc | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,535 in reported general payments places this provider in the 75th percentile of 200 sleep medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 13 | $181,148 |
| QuviviqDaridorexant Hcl | 41 | $25,669 |
| HorizantGabapentin Enacarbil | 16 | $12,843 |
| NeuproRotigotine | 12 | $9,949 |
| Gabapentin | 143 | $1,539 |
| Temazepam | 85 | $1,444 |
| Eszopiclone | 38 | $598 |
| Armodafinil | 19 | $505 |
| Methylphenidate Hcl | 18 | $484 |
| Modafinil | 22 | $472 |
| Clonazepam | 43 | $415 |
| Trazodone Hcl | 47 | $316 |
| Dextroamphetamine Sulfate | 11 | $301 |
| Methadone Hcl | 22 | $204 |
| Alprazolam | 18 | $40 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Idorsia Pharmaceuticals US IncQuviviq | $71 | $25,66941 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $105 | $12,84316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 200 sleep medicine providers in California.
Other sleep medicine in Murrieta
- Lisa ShivesSan Diego$1.4M
- Haramandeep SinghSan Ramon$1.1M
- Atul MalhotraSan Diego$771K
- Logan SchneiderStanford$506K
- Tony MasriLos Gatos$327K
- Sam KashaniSanta Monica$221K
- Emmanuel MignotStanford$135K
- Jerome HesterPalo Alto$74K
- Mark BuchfuhrerDowney$70K
- Clete KushidaStanford$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.